Skip to main content
v2026.11,986 entries · CC-BY 4.0

ICH Q3B: Impurities in New Drug Products

A registration-focused guide to ICH Q3B scope, degradation-product reporting, analytical evidence, specifications and qualification.

Written and maintained by CASRAI Editorial Board

Published

On this page

ICH Q3B(R2) explains how registration applicants should report, identify and qualify degradation products in new drug products made from chemically synthesised new drug substances. Its practical purpose is to connect the finished product’s impurity profile with suitable analytical methods, batch evidence and justified specifications.

What it is and who runs it

ICH Q3B is the harmonised guideline Impurities in New Drug Products. Developed through the ICH process, it addresses the information supporting a registration application. FDA publishes its implementation as guidance for industry through the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. EMA lists the corresponding scientific guideline, and Australia’s TGA identifies its adopted version.

As described on the official page on 2026-11-15, EMA’s current effective listing is Q3B(R2). FDA’s document title also carries “Revision 3”: the document explains that this correction concerned its cover-page date, with other information unchanged. These labels should not be interpreted as evidence of a separate ICH Q3B(R3) technical standard.

FDA expressly describes its guidance as recommendations representing its current thinking. It does not independently impose legally enforceable responsibilities, and an alternative approach can be used if it satisfies applicable statutes and regulations. A submission team therefore needs to distinguish the scientific recommendations from the legal requirements of its receiving authority. The downloadable data table below compares the official regional document presentations and their stated qualifications.

Eligibility: scope and exclusions

Applicability depends on the product and impurity category. The official text addresses registration applications for new drug products containing chemically synthesised drug substances that have not previously been registered in the relevant region or member state. This is a scope test for a quality dossier.

The covered impurities are degradation products of the drug substance, including products of its reaction with an excipient or the immediate container closure system. An impurity already present in the drug substance generally does not need separate finished-product monitoring or specification under Q3B unless it is also a degradation product. The applicant should explain why excluded peaks or impurities fall outside the degradation-product assessment.

A packaging distinction matters: a reaction between the drug substance and its immediate packaging falls within this definition, while a substance extracted or leached from that packaging is outside Q3B’s stated scope. Impurities originating from excipients themselves are also excluded. A chromatogram can contain several categories at once; the appearance of a peak alone does not establish its regulatory category.

The guideline excludes biological and biotechnological products, peptides, oligonucleotides, radiopharmaceuticals, fermentation products and their semisynthetic derivatives, herbal products, and crude animal or plant products. It also excludes polymorphic forms, enantiomeric impurities and extraneous contaminants more appropriately treated as GMP issues. New drug products used during clinical research are outside its intended application, although the text separately discusses the usefulness of its thresholds later in development.

What it requires: reporting, identification and qualification

Q3B separates three actions that answer different questions. Reporting documents the measured degradation-product content. Identification establishes structural characterisation. Qualification acquires and evaluates evidence supporting the biological safety of a degradation product or profile at the proposed levels. An analytical result, a chemical identity and a qualification rationale are different parts of the evidence package.

The guideline defines a separate threshold for each action and provides the applicable threshold tables in Attachment 1. Crossing a reporting threshold does not by itself establish that structural identification or qualification has been completed. Conversely, a degradation product suspected to have unusually potent toxic or pharmacological effects can warrant analytical attention below the usual identification threshold. The framework therefore combines threshold-based action with substance-specific scientific assessment.

Analytical procedures should be validated for their intended detection and quantitation tasks, including specificity for specified and unspecified degradation products. The quantitation limit should be no higher than the reporting threshold. Relevant stressed samples can support specificity work, while peaks attributable to the drug substance, synthesis impurities or excipients should be labelled and their origins discussed in validation documentation.

Quantitation also needs an explicit analytical basis. The text permits comparison against an appropriate reference standard or the drug substance itself, with reference materials characterised for their intended use. Where detector responses differ, the correction or conservative estimation approach needs explanation. Assuming equivalent response without discussing that assumption leaves a gap between peak response and the reported impurity result.

If structural identification proves infeasible, Section II calls for a summary of the laboratory work documenting the unsuccessful attempts in the registration application. An unresolved structure therefore still needs an evidence trail; merely naming the peak does not document the identification effort.

Application or compliance steps

FDA Sections II–VI organise the scientific work around degradation pathways, analytical evidence, batch reporting, specifications and qualification. The following sequence translates those recommendations into a dossier-preparation workflow; it does not prescribe a laboratory procedure.

  1. Establish the degradation rationale. Summarise potential pathways and the products observed during manufacture and stability studies. Include interactions involving excipients and immediate packaging. Explain exclusions and compare development-batch profiles with profiles representative of the proposed commercial process.
  2. Document method suitability. Provide validation evidence, peak assignments and relevant analytical assumptions. Discuss differences between methods used during development and those proposed for the commercial product so that the batch comparisons remain interpretable.
  3. Assemble numerical batch results. Include relevant clinical, safety and stability batches together with commercially representative batches. Report results numerically rather than substituting a general statement that the batch meets its limit.
  4. Justify the proposed specification. Explain why individual degradation products are included or excluded. Account for the qualified level, stability-related increases, proposed shelf life and recommended storage conditions. Each individual acceptance criterion should be no higher than its qualified level.
  5. Connect qualification evidence. Explain the safety basis supporting the proposed criteria. Where the qualification threshold is exceeded and existing evidence does not support the proposed level, the guideline discusses additional evidence or reducing the degradation-product level.

For submission organisation, the eCTD Module 3 quality guide provides the broader dossier map. Within the Q3B evidence itself, the batch record should retain identity, strength and size; manufacturing date, site and process; immediate packaging; individual and total degradation-product content; batch purpose; analytical method reference; associated drug-substance batch; and stability storage conditions.

The evidence map below is an editorial synthesis of FDA’s recommendations. It distinguishes the supporting records from the decisions they support, rather than treating a single impurity spreadsheet as the entire submission.

Decision or task Supporting evidence Q3B location
Explain the degradation profile Pathway assessment, laboratory findings and development/commercial batch comparison Section II
Show analytical suitability Specificity validation, labelled peaks and quantitation assumptions Section III
Report batch content Numerical individual and total results, chromatograms or equivalent data, and batch metadata Section IV
Support specification entries Inclusion/exclusion rationale, stability trends and proposed acceptance criteria Section V
Support qualification Safety rationale and relevant evidence for the proposed degradation-product levels Section VI

Typical timeline phases

Q3B describes an evidence progression rather than a fixed application calendar. Its recommendations connect product development, evaluation of the proposed commercial process, stability information and preparation of the registration package. The following phases summarise that progression without assigning invented deadlines or study durations.

Development and characterisation: laboratory and product-development studies establish likely degradation pathways and the observed profile. Analytical procedures and assumptions may evolve, so the eventual registration application should explain relevant differences between development methods and proposed commercial methods.

Commercial-process comparison: batches representative of the proposed process are compared with development batches, with differences discussed. Despite the exclusion of clinical research-stage products from its intended scope, Section VI says the thresholds can be useful for evaluating new degradation products in later development batches made by the proposed commercial process. That statement does not make Q3B a universal clinical-trial impurity rule.

Stability assessment and registration assembly: the degradation profile observed under recommended storage conditions informs identification work and the proposed specification. The dossier brings together relevant long-term and accelerated stability chromatograms or equivalent data, analytical validation evidence, numerical batch results and qualification rationale. Q3B connects those records to proposed shelf life and storage conditions; it does not establish an authority’s review deadline.

Common mistakes

The following checks follow directly from the guideline’s distinctions. They are checks on dossier completeness, rather than claims about the frequency of regulatory findings.

  • Treating every impurity as a Q3B degradation product. Separate drug-substance process impurities, excipient-origin impurities and leachables from the covered degradation and reaction products. Explain the classification.
  • Equating “identified” with “specified”. A specified degradation product has its own listed acceptance criterion. It can be structurally identified or still unidentified. Use an appropriate analytical descriptor for an unidentified entry and state the assumptions behind its quantitation.
  • Replacing measured results with pass/fail language. Section IV calls for numerical batch results and supporting analytical information. A compliance statement does not convey the measured individual and total degradation-product profile.
  • Using the threshold as the complete specification rationale. Section V also considers qualification, stability increases, proposed shelf life, storage and manufacturing and analytical variation. A threshold table cannot replace that product-specific justification.
  • Leaving the detector-response assumption unstated. Where an impurity is estimated using another substance’s response, explain the relevant correction or conservative assumption and characterise the reference material for its use.
  • Omitting the total or unspecified category. Where applicable, the specification includes specified identified products, specified unidentified products, a general criterion for unspecified products and a criterion for total degradation products.

These distinctions also explain why a larger acceptance criterion cannot be justified simply by a higher observed batch result. The guideline says an individual criterion should not exceed the qualified level. Significant batch-to-batch variation can indicate inadequate process control; it needs scientific evaluation rather than automatic expansion of the specification.

Q3B sits within a group of complementary pharmaceutical quality guidelines. FDA specifically directs applicants to Q3A for basic principles and Q3C where appropriate, while distinguishing Q3B’s impurity listing from Q6A’s specification role. EMA’s impurity directory separately lists the elemental- and mutagenic-impurity frameworks.

Guideline Subject Relationship to this page
ICH Q3A(R2) Impurities in new drug substances Companion substance-stage guidance; Q3B addresses degradation products in the finished product
ICH Q3C Residual solvents Separate solvent framework referenced by Q3B
ICH Q3D Elemental impurities Separate impurity category listed in EMA’s directory
ICH Q6A Test procedures and acceptance criteria for chemical drug substances and products Specification context cross-referenced by Q3B
ICH M7 DNA-reactive mutagenic impurities Distinct assessment and control framework listed alongside the Q3 guidelines

For those separate topics, CASRAI’s guides explain ICH Q3C residual-solvent controls and ICH Q3D elemental-impurity assessment. Their categories should remain distinguishable in the evidence package: a finished-product degradation assessment does not, by its name alone, document every other kind of impurity assessment.

Sources

Data: ICH Q3B official document labels and regional qualifications

Original cross-authority compilation of FDA, EMA and TGA presentations of ICH Q3B. Each row combines the authority, document label and the implementation qualification stated in its official guidance or listing. This compares document presentation, not legal equivalence or review timelines.

ICH Q3B official document labels and regional qualifications
AuthorityOfficial presentationStated qualificationSource location
FDAQ3B(R2) Impurities in New Drug Products, Revision 3Nonbinding recommendations; an alternative approach can satisfy applicable statutes and regulations. Revision 3 corrects the cover-page date, with other information unchanged.FDA guidance: opening disclaimer and title-page footnote
EMAICH Q3B(R2), Step 5; CPMP/ICH/2738/99Listed as the current effective version for impurities in new drug products in registration applications.EMA Q3B scientific-guideline listing
TGAAdopted ICH Q3B(R2); CPMP/ICH/2738/99TGA annotations are nil. EU legislation referenced in adopted EU guidelines does not apply to TGA evaluation of medicines.TGA Q3B adoption page: About this guideline

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about ICH Q3B: Impurities in New Drug Products

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →